Luminus Micro Now Poised to Launch Groundbreaking Microsurgical Devices, Garnering Favorable Industry Attention
Q2 2024
After years of innovative engineering, patents and market development, LuminusMicro is now prepared to launch a series of powerful new microsurgical devices. LuminusMicro devices are proven to give surgeons access to key anatomy never seen outside of an operating room, where they achieve unmatched diagnostic accuracy and are also able to deliver treatments with new safety, speed and precision.
Meeting the highest standard for contamination and infection risks, LuminusMicro devices are 100% sterile (disposable – never needing to be cleaned for reuse on another patient). The operating system is portable and nearly free to adopt, offering immediate benefits for all participants in healthcare. Many top surgeons agree that Luminus devices are equipped to bring today’s minimally invasive surgeries into the next era of micro-procedures.
BUSINESS STRATEGY
Considering the micro-size and new capabilities that LuminusMicro devices offer, our surgeon advisors have identified a series of high-volume, high-impact procedure opportunities in every surgical market. Management plans to build a microsurgical brand to deliver breakthroughs into each space, with keen focus on ENT and the Ortho-Spine spaces. Overall, the Luminus business opportunity exceeds a billion US dollars in each surgical market (the long-term portfolio includes 12 potential microsurgical device brands).
TEAM & ASSETS
The Luminus executive team brings together an impressive list of successes where they helped to create and commercialize market-changing, global products that each generated over a $1Billion in sales. Examples include Apple Computers, 3D printing, Arthroscopic Surgery, and several pharmaceutical products. To carry out training and sales, a national distribution network also stands ready.
NEXT STEPS
With Luminus Gen-1 (“X1”) products refined for volume production, management received favorable bids from (5) top US manufacturers to scale up production and complete FDA clearance. Recent reports confirm that Luminus devices are Class II endoscopes – the fastest devices at gaining FDA clearance – often in less than 35 days once production, case impacts and training protocols are documented.
NEW CAPITAL / LIMITED SHAREHOLDER OPPORTUNITY
Multiple healthcare securities firms have agreed on favorable terms and budgets to capitalize the first Luminus product launch. This budget completes key milestones including the 510(k) certification, extinguishing debt, and engaging first live human case use with advising surgeons in key regions. From there sales, operations and engineering staff will expand to support a national sales expansion.
Factors in the firm’s decision to engage Luminus Holdings included the following achievements of management, despite pandemic-related challenges:
● Advancing engineering/pre-production to the manufacture stage
● Validation of demand for the products and straightforward FDA paths
● Expansion of the executive and sales teams, and intellectual property assets
● Expansion of financial resources who intend to invest at specific milestones
